Aspen, Saudi Chemical Company Holding and its subsidiary AJA Pharma enter into a memorandum of understanding.

Dubai, United Arab EmiratesAspen Healthcare FZ LLC (“Aspen Healthcare”), a subsidiary of Aspen Pharmacare Holdings Limited (“Aspen”), a global specialty and branded multinational pharmaceutical company, has entered into a memorandum of understanding (“MOU”) with Saudi Chemical Company Holding (“SCCH”), a well-known company in the local market of the Kingdom of Saudi Arabia, and its subsidiary AJA Pharmaceutical Industries Ltd (“AJA Pharma”), a recognized manufacturer of pharmaceutical products.


In terms of this MOU, Aspen, SCCH and AJA Pharma will further expand their existing partnership to strategically collaborate on an extended portfolio of products, the manufacturing of products in the Kingdom of Saudi Arabia, and the export of products to existing Aspen markets. 

Daniel Vella Friggieri, Aspen Healthcare Regional CEO for Middle East, North Africa & Turkey, said, “We are excited to announce our strategic collaboration with Saudi Chemical Company Holding and its subsidiary AJA Pharma. This agreement endorses Aspen’s continuous commitment to align with the Kingdom’s 2030 vision and our drive to provide high quality healthcare products to patients in the Kingdom, the Middle East region and beyond”.


Thamer Almuhid, Saudi Chemical Company Holding Group CEO commented, “Nowadays technology and globalization play a more important role than ever; having a strategic partnership between Aspen and AJA Pharma will ensure that both the aspects of technologies and global market access are fulfilled towards achieving the KSA 2030 vision. We are pleased to partner with a trusted partner like Aspen and look forward to a prosperous strategic partnership”.










Closed Period

Aspen is in a closed period from 1 January until the publication of our interim results on the JSE SENS platform scheduled to be released on 1 March 2023.

The live presentation will take place in Cape Town at 08h30 on 2 March 2023.